KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 117 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $46,000 | -74.0% | 12,200 | -71.7% | 0.00% | – |
| Q1 2018 | $177,000 | +205.2% | 43,072 | +247.4% | 0.00% | – |
| Q4 2017 | $58,000 | -58.9% | 12,400 | -45.7% | 0.00% | -100.0% |
| Q1 2017 | $141,000 | -6.6% | 22,848 | -19.9% | 0.00% | 0.0% |
| Q3 2016 | $151,000 | -50.2% | 28,511 | -37.7% | 0.00% | 0.0% |
| Q2 2016 | $303,000 | -49.9% | 45,749 | -64.7% | 0.00% | -66.7% |
| Q1 2016 | $605,000 | +40.7% | 129,645 | +52.1% | 0.00% | 0.0% |
| Q4 2015 | $430,000 | +36.9% | 85,222 | -4.5% | 0.00% | +50.0% |
| Q3 2015 | $314,000 | +35.3% | 89,276 | +283.9% | 0.00% | 0.0% |
| Q2 2015 | $232,000 | +69.3% | 23,252 | +115.3% | 0.00% | +100.0% |
| Q1 2015 | $137,000 | -60.1% | 10,800 | -56.7% | 0.00% | -66.7% |
| Q3 2014 | $343,000 | -85.3% | 24,969 | -81.7% | 0.00% | -88.5% |
| Q1 2014 | $2,326,000 | – | 136,516 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management I, LLC | 1,312,006 | $22,357,000 | 15.70% |
| VHCP Management, LLC | 1,000,273 | $17,045,000 | 8.86% |
| HARVEY CAPITAL MANAGEMENT INC | 915,800 | $15,605,000 | 6.22% |
| Baupost Group | 6,310,850 | $107,537,000 | 2.60% |
| SECTORAL ASSET MANAGEMENT INC | 3,537,590 | $60,281,000 | 2.48% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 587,504 | $10,011,000 | 2.31% |
| Knoll Capital Management, LLC | 200,000 | $3,408,000 | 1.76% |
| Camber Capital Management LP | 1,250,000 | $21,300,000 | 1.67% |
| NORTHPOINTE CAPITAL LLC | 877,875 | $14,958,000 | 1.52% |
| DAFNA Capital Management LLC | 100,000 | $1,704,000 | 1.46% |